Xeris Biopharma Holdings, Inc. (XERS)

Market Cap	520.29M
Revenue (ttm)	187.36M
Net Income (ttm)	-63.11M
Shares Out	149.08M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,471,746
Open	3.350
Previous Close	3.410
Day's Range	3.350 - 3.569
52-Week Range	1.690 - 3.870
Beta	1.24
Analysts	Buy
Price Target	4.87 (+39.54%)
Earnings Date	Nov 8, 2024

About XERS

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 377
• Stock Exchange: NASDAQ
• Ticker Symbol: XERS
• Website: https://www.xerispharma.com

Financial Performance

In 2023, Xeris Biopharma Holdings's revenue was $163.91 million, an increase of 48.68% compared to the previous year's $110.25 million. Losses were -$62.26 million, -34.23% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for XERS stock is "Buy." The 12-month stock price forecast is $4.87, which is an increase of 39.54% from the latest price.

Price Target

$4.87

(39.54% upside)

Analyst Consensus: Buy